Drugs Made In America Acquisition Corp.

Drugs Made In America Acquisition Corp. (Nasdaq: DMAAR) is a blank-check company targeting the domestic pharmaceutical and drug manufacturing sector, reflecting heightened investor interest in reshoring U.S. medicine supply chains. The SPAC filed a 10-Q with the SEC on August 14, 2025 (accession 0001213900-25-076681), indicating it remains an active reporting company continuing its search for a business combination target. DMAAR sits within the broader healthcare and life sciences SPAC universe, where domestic manufacturing mandates and biosecurity policy tailwinds have drawn sponsor attention. Visit SpacDesk and sign up for full data on DMAAR, including deal timelines, sponsor details, and comparable transaction analytics.